The Department of Justice made a narrow but consequential move on April 23, rescheduling certain marijuana products - specifically FDA-approved formulations and state-licensed medical cannabis products - from Schedule I to Schedule III under the Controlled Substances Act. For dispensary operators and cannabis businesses, the immediate instinct might be to call this a win. The reality is messier. Federal and state law remain in fundamental conflict for most of what the licensed cannabis industry actually sells.
What Actually Changed - and What Didn't
The practical scope of the April order is narrower than the headlines suggest. Two categories of marijuana product moved off Schedule I: those approved by the FDA, and products regulated under a state medical marijuana license. That second category matters directly to licensed dispensaries operating in the forty states, three territories, and Washington, D.C., that permit medical cannabis as of mid-2025. If a patient is purchasing from a properly licensed medical program and following state rules, they are no longer violating federal law. That's not nothing.
But here's the catch - recreational cannabis, which is now permitted in twenty-four states and D.C., remains a Schedule I substance under federal law. For vertically integrated operators running both medical and adult-use programs under the same roof, or even through the same POS system and inventory infrastructure, that distinction creates real compliance exposure. The same business that now has partial federal legitimacy on its medical side is still running an operation the federal government classifies as trafficking on the adult-use side.
Heather Trela of the Rockefeller Institute of Government has been direct about the limits: the order does not legalize marijuana in states that haven't already passed their own programs, and it doesn't make recreational use legal anywhere at the federal level. It resolves one narrow conflict. It leaves most of the others standing.
The 280E Question and What It Means for Operator Economics
For cannabis business owners, one of the most consequential downstream questions is how this rescheduling interacts with Section 280E of the Internal Revenue Code. Under current federal tax law, businesses that traffic in Schedule I or Schedule II controlled substances cannot deduct ordinary business expenses - no deductions for rent, payroll, marketing, or POS software costs. This has made effective tax rates punishing for licensed dispensaries, sometimes reaching effective rates that leave operators paying taxes on gross profit rather than net income.
Schedule III substances are not subject to 280E. So for the portion of a cannabis business covered by the rescheduling - state-licensed medical products - there is an argument that 280E no longer applies. That would be a meaningful financial shift for medical-only operators. For multi-state operators or retailers who sell both medical and adult-use product, the picture is murkier. Recreational cannabis stays on Schedule I. Whether the IRS would accept a bifurcated accounting approach - 280E applies to adult-use revenue but not medical - is an open question with significant legal and audit risk attached to it.
Operators and their CFOs should be working with cannabis-specialized tax counsel before adjusting how they file. This is not a situation where the cautious move is to assume the benefit automatically applies.
Research Access Opens; Business Uncertainty Doesn't Close
One genuinely significant consequence of moving medical cannabis to Schedule III is what it does for research. Schedule I classification created a feedback loop that stunted the evidence base for cannabis therapeutics: it was legally difficult to study a substance the federal government simultaneously classified as having no accepted medical use. Researchers faced regulatory obstacles - including DEA licensing requirements and limits on source material - that other drug researchers didn't. That constrained the clinical trial pipeline and left operators unable to make substantiated claims about their products' therapeutic value under FDA standards.
Rescheduling removes some of those obstacles for the medical category. More rigorous studies become possible. Over time, that matters for how dispensaries frame medical sales, how state medical programs justify their formularies, and how product liability questions get resolved if consumer safety issues arise. It won't change compliance obligations tomorrow. But better-quality research eventually shapes regulation, and regulation shapes what's on the dispensary shelf and how it's labeled.
What's striking here is the gap between where research currently sits and where it needs to go. Studies on cannabis's long-term effects, drug interactions, and dose-response relationships remain limited in sample size and scope. The industry has been selling products for years without the kind of clinical evidence base that regulators would normally require. Rescheduling doesn't resolve that history - it opens a door toward eventually addressing it.
The Broader Federal-State Tension Isn't Going Anywhere
The patchwork problem hasn't been solved. Most cannabis operators already knew that federal law and state law were in conflict; they built their entire compliance infrastructure around that reality. Seed-to-sale tracking systems like METRC exist because states built their own enforcement architecture in the absence of federal coordination. Cashless payment workarounds - cashless ATMs, PIN debit structures, and the persistent cash-heavy nature of dispensary retail - persist largely because federal banking law makes major financial institutions unwilling to serve Schedule I businesses. That calculus changes slowly, if at all, for the adult-use side.
The DOJ has signaled it will begin a broader rescheduling process starting at the end of June, including administrative hearings. That process is longer and more formal. A legal challenge already filed by Smart Approaches to Marijuana argues the April order exceeded the administration's authority and violated administrative rulemaking requirements. If that challenge succeeds, even the narrow gains from the April order could be reversed.
Meanwhile, Congress - the body with the most direct authority to resolve federal-state conflict - hasn't moved meaningful cannabis legislation. Provisions in annual budget bills that bar the DOJ from using federal funds to interfere with state medical programs have held, but they are riders, not permanent law. They can disappear in any budget cycle.
To put it plainly: the April rescheduling is a real development, not a symbolic one. But licensed cannabis businesses - dispensary operators, wholesalers, ancillary vendors - should be reading it as incremental progress in a long and unresolved regulatory conflict, not as a signal that federal-state alignment is close. The compliance obligations that define daily operations haven't changed. The tax exposure on adult-use revenue hasn't changed. And the fundamental question of whether recreational cannabis will ever achieve federal legal status remains as open as it has ever been.
